The need for more consistency around the management of hepatitis B during immunosuppression with cancer treatment was one of the drivers for new guidelines soon to be endorsed by five professional societies. Speaking at the Australasian Society for Infectious Diseases (ASID) Annual Scientific Meeting on the Gold Coast, Dr Joseph Doyle said a second reason ...
Avoid hep B reactivation during cancer therapy
By Mardi Chapman
22 May 2018